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Abstract: Recent literature confirms the ergogenic effect of acute caffeine intake to increase muscle 
strength and power in men. However, the information about the effect of caffeine on muscle 
performance in women is uncertain and it is unknown whether its ergogenicity is similar during 
the menstrual cycle. The goal of this investigation was to assess the effect of acute caffeine intake on 
mean and peak velocity of half-squat exercise during three different phases of the menstrual cycle. 
Thirteen trained eumenorrheic athletes (age = 31 ± 6 years; body mass = 58.6 ± 7.8 kg) participated 
in a double-blind, crossover and randomized experimental trial. In the early follicular (EFP), late 
follicular (LFP) and mid luteal phases (MLP), participants either ingested a placebo (cellulose) or 3 
mg/kg/bm of caffeine in an opaque and unidentifiable capsule. In each trial, participants performed 
a half-squat exercise at maximal velocity with loads equivalent to 20%, 40% 60% and 80% of one 
repetition maximum (1RM). In each load, mean and peak velocity were measured during the 
concentric phase of the exercise using a rotatory encoder. In comparison to the placebo, a two-way 
ANOVA showed that the ingestion of 3 mg/kg/bm of caffeine increased mean velocity at 60% 1RM 
in EFP (Δ = 1.4 ± 2.7%, p = 0.04; ES: 0.2 ± 0.2) and LFP (Δ = 5.0 ± 10.4%, p = 0.04; ES: 0.3 ± 0.4). No other 
statistical differences were found for the caffeine-placebo comparison for mean velocity, but caffeine 
induced an ergogenic effect of small magnitude in all of the menstrual cycle phases. These results 
suggest that the acute intake of 3 mg/kg/bm of caffeine induces a small effect to increase movement 
velocity during resistance exercise in eumenorrheic female athletes. The positive effect of caffeine 
was of similar magnitude in all the three phases of the menstrual cycle. 
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1. Introduction 
Despite the equivocal findings of previous original investigations [1–4], emerging literature 
using meta-analysis suggests that acute caffeine intake is able to increase muscle strength and power 
[5,6]. This new information has given support to consider caffeine as an effective strategy to increase 
performance in resistance exercise with a relatively low prevalence of side effects when taken in the 
recommended doses (i.e., 3 to 9 mg per kilogram of body mass: mg/kg/bm [7]). However, most of this 
body of research has been carried out only on male samples. For example, in the meta-analyses by 
Grgic et al., about caffeine ergogenicity on muscle performance [5,6], only 9.7%–22.2% of the total 
sample used for these analyses were women. In fact, a detailed analysis of [5] revealed a significant 
increase in upper body muscle performance with caffeine in men while this effect was not present in 
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women. Thus, caution is needed when assuming that the ergogenicity of caffeine for resistance 
exercise is also present in women [7].  
Although some investigations have found an ergogenic effect of caffeine on muscle performance 
in women [1,8,9], this has not always been the case [10]. In general terms, it seems that the 
effectiveness of caffeine in increasing resistance exercise performance is lower in women than in men 
[11]. Sabblah et al. (2015) examined the effects of 5 mg/kg/bm of caffeine on the bench press and squat 
one repetition maximum (1RM) in both men and women and found there was a tendency towards 
an ergogenic effect of caffeine in the weight lifted in males only. Nevertheless, one common limitation 
of these investigations is that none of the studies controlled for the potential effects of the menstrual 
cycle on muscle performance [12] nor for the possible interaction of caffeine with the fluctuations of 
female sex hormones during the menstrual cycle [13,14].  
Although the pharmacokinetics of acute caffeine intake are similar in the follicular, ovulatory 
and luteal phases [15,16], ethinylestradiol might induce an inhibition of the activity of CYP1A2, an 
enzyme responsible for the metabolism of caffeine [17]. In this sense, the administration of low-doses 
of estrogen-containing oral contraceptives reduces the rate of plasma clearance of caffeine and 
increases the time necessary to reach peak plasma caffeine concentration [18]. Then, the ergogenicity 
of caffeine to increase muscle strength might be higher in the days when the concentration of natural 
estrogens is higher (i.e., late follicular phase) because the serum caffeine concentration would remain 
longer than in the menstrual cycle phases were serum estrogen concentrations are low (i.e., menses 
and luteal phase) [19]. In addition, previous investigations have reported higher caffeine-induced 
effects on cardiovascular and subjective variables in the follicular phase than in the luteal phase 
[13,20]. With this background of knowledge, to date it is difficult to ascertain whether acute caffeine 
intake could improve muscle performance in women during resistance exercise. Furthermore, it is 
unknown if the potential ergogenic effect of caffeine on muscle performance is present, and of similar 
magnitude, during all the different phases of the menstrual cycle. Therefore, the main aim of this 
investigation was to determine the effect of caffeine intake on muscle performance during the early 
follicular, late follicular and mid-luteal phases of the menstrual cycle in eumenorrheic females. 
2. Materials and Methods  
2.1. Participants 
Thirteen healthy trained women volunteered to participate in this study (age = 31 ± 6 years; body 
mass = 58.6 ± 7.8 kg; body height = 1.66 ± 0.06 m; body fat percentage = 14.5 ± 6.5%). All of the 
participants were competitive athletes and fulfilled the following inclusion criteria: a) age between 
18 and 40 years; b) active training (including a combination of running, cycling and swimming 
practice) of ~2 h/day, at least 5 days/week for the previous two months; c) low caffeine consumption 
(i.e., <100 mg/day); and d) steady duration of their menstrual cycle for the previous 4 months. 
Participants were excluded if they reported a) any type of injury within the previous six months; b) 
a positive smoking status; c) medication usage within the previous month; d) previous history of 
cardiopulmonary diseases; e) oral contraceptive use; f) allergy to caffeine; or g) any type of menstrual 
disorders such as dysmenorrhea, amenorrhea, or strong symptoms associated with pre-menstrual 
syndrome. Participants were included if they had at least six months of resistance training experience 
(16 ± 8 months of experience in this sample), and were familiar with the half-squat exercise. All this 
information was obtained from a pre-participation screening that included a medical and training 
history as well as a food frequency questionnaire. One week before the experiment protocol, 
participants were fully informed of the procedures and the risks associated with the experiment. 
Participants signed their informed written consent prior to participating in the investigation. The 
study was approved by the Camilo José Cela University Research Ethics Committee. All research 
protocols were in accordance with the latest version of the Declaration of Helsinki. 
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2.2. Experimental Design  
A double-blind, placebo-controlled, crossover and randomized experimental design was used 
in this investigation. In each of the following three phases of the menstrual cycle: early follicular 
(EFP), late follicular (LFP) and the mid-luteal (MLP), each participant completed 2 experimental trials 
making a total of 6 identical experimental trials (Figure 1). In each trial, leg muscle performance was 
measured using a half-squat exercise at maximal velocity with loads equivalent to 20%, 40% 60% and 
80% of one repetition maximum (1RM). In each load, mean and peak velocity were measured during 
the concentric phase of the exercise. During each of these three menstrual cycle phases, and in a 
randomized order, participants ingested an opaque and unidentifiable capsule containing either 
caffeine (3 mg/kg/bm; 100% purity, Bulk Powders, UK) or an inert substance as a placebo (e.g., 
cellulose; 100% purity, Guinama, Spain). These two trials within each phase were separated by 48 h 
to allow recovery, testing reproducibility, and substance elimination. The first menstrual cycle phase 
under investigation was randomly assigned, and a similar number of participants started in EFP (5 
participants), LFP (4 participants) and MLP (4 participants). An alphanumeric code was assigned to 
each trial by a person independent of the study. This was done in order to double-blind the 
participants and researchers to the trial order and substances. Menstrual cycle phase identification 
was carefully conducted according to the methodological considerations raised by Janse de Jonge [21] 
and with the help of a period tracker application, tympanic temperature, body mass changes and 
assessment of the urinary peak of the luteinizing hormone.  
 
Figure 1. Experimental design of the investigation.  ad hoc questionnaire;  Menses;  Body 
mass measurement;  Tympanic temperature measurement;  Caffeine/placebo trials;  
measurement of urinary peak of the luteinizing hormone;  Protocol of resistance exercise. 
This image displays the protocol followed by an athlete with a 28 day menstrual cycle. After 
participants had recorded the regularity and length of their menstrual cycles for 4 months, caffeine 
(3 mg/kg/bm) or a placebo was administered in three different phases of the menstrual cycle: early 
follicular, late follicular and mid-luteal. Muscle performance were measured 60 min after the 
assigned capsule was ingested. They then measured their basal tympanic temperature, body mass, 
and increases in luteinizing hormone using urine test strips to determine the onset of each menstrual 
cycle phase.  
2.3. Standardizations, Familiarization and Pre-Experimental Trial 
Once participants had fulfilled all the inclusion/exclusion criteria and signed the informed 
consent, they were encouraged to avoid nutritional supplements and sympathetic-adrenergic 
stimulants for the duration of the study. Participants were explicitly encouraged to avoid any 
nutritional source of caffeine (coffee, tea, soft and energy drinks, chocolate), and were informed about 
the necessity of maintaining their habitual training routines and a stable state of physical fitness 
during the experiment. Two weeks before the onset of the experiment, participants performed two 
familiarization sessions with the testing protocol in order to minimize any learning effects during the 
experiment. One week before the experiment, a 1RM test was performed to standardize the loads in 
the subsequent experimental sessions. For this 1RM measurement, participants commenced with sets 
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of increasing loads estimated to be between 20% and 90% of 1RM, as previously described by Banyard 
et al. [22]. Then, the first 1RM attempt was performed with a maximum of five 1RM attempts 
permitted. After any successful 1RM attempt, the barbell load was increased between 0.5 and 2.5 kg 
until the last successful lift with a correct technique was obtained, which was categorized as 1RM 
(96.5 ± 17.1 kg). Two minutes of recovery were taken between 1RM attempts. On this day, participants 
were nude-weighed (±50 g, Radwag, Poland) in order to properly calculate caffeine dosage. The day 
before each trial, participants performed light, standardized training and a self-selected 
precompetitive diet/fluid routine was kept and recorded for replication. Participants were also 
required to refrain from intaking alcohol and to maintain a sleep pattern with at least 8 h of sleep the 
day before each trial.  
2.4. Experimental Protocol 
Participants performed six identical experimental trials starting with the menstrual cycle phase 
that was randomly assigned. Trials were performed in a laboratory, in the morning (between 09:00 
and 11:00) and under similar environmental conditions (22–23 °C and 60% humidity; OH1001, OH 
Haus, Spain). Participants arrived at the laboratory in a fed state (~3 h after their last meal). In each 
experimental trial, the participants were nude-weighed after voiding (Tanita BF 350, Tanita 
Corporation, Tokyo, Japan), and then ingested the assigned capsule with caffeine or a placebo—and 
rested supine for 45 min. They subsequently performed a standardized 15 min warm-up protocol 
that included pedaling on a cycle ergometer and a submaximal attempt on the half squat machine. 
Then, participants performed two attempts of the half-squat exercise with loads that represented 
20%, 40%, 60% and 80% of their 1RM—measured in the pre-experimental trial. The testing was 
performed on a Smith Machine (Technogym, Barcelona, Spain) in which 2 vertical guides regulated 
the barbell movement. Participants were encouraged to produce each repetition at their maximal 
velocity, and they could repeat any attempt if they considered that this was not maximal. Two 
minutes of passive rest were allocated between the attempts with the same load and three minutes of 
resting between different loads. The complete range of motion for the half squat exercise consisted of 
lowering the body by bending the knees to a 90° angle until touching a bench with the buttocks. In 
this position, participants executed a maximal velocity knee extension and thus, the concentric phase 
of the exercise was isolated and measured. Execution technique and motivation were standardized 
and monitored by 2 experienced researchers for reliability of the experimental conditions. In each 
attempt, barbell displacement in the concentric phase of the movement was recorded with a rotatory 
encoder and associated software (Isocontrol, EV-Pro, Spain) and mean and peak velocity (in m/s) 
were measured. The attempt with the highest barbell displacement velocity in each load was used 
for statistical analysis. With this information, the estimated 1RM was calculated [23] in all phases to 
ensure that 1RM remained unchanged throughout the experiment (EFP: 97.0 ± 23.2 kg; LFP: 98.5 ± 
18.1 kg; MLP: 98.1 ± 22.2 kg).  
2.5. Determination of Menstrual Cycle Phase 
The EFP, LFP and MLP phases were selected for investigation because they represent main 
events occurring during the menstrual cycle (i.e., menses, pre-ovulation and peak progesterone 
concentration, respectively). The duration of the menstrual cycle and the onset of each phase were 
accurately determined by using (a) a period tracker application; (b) measurement of basal tympanic 
temperature and body mass changes; and (c) assessment of the urinary peak of the luteinizing 
hormone, following established recommendations [21]. The duration of each participant’s menstrual 
cycle was recorded for a minimum of 4 months prior to the onset of the experiment for a valid 
characterization of length. This information was obtained using a mobile application (Mycalendar®, 
Period-tracker, Hong Kong, China) together with a menstruation diary, which included the date of 
menses, length of menses, and discomfort in the days preceding and during the menses. All 
participants had a regular menstrual cycle for the four months previous to the experiment (27 ± 2 
days, range = 24–31 days) and were considered as eumenorrheic. During the familiarization period, 
participants were trained on how to measure their own basal tympanic temperature and to obtain 
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valid body mass measurements. A digital thermometer (model HDT8208C, Nursal Ear Thermometer, 
Dongguan, China) and a digital scale (BT200, Daga, Barcelona, Spain) were provided for each 
participant to obtain data every morning immediately after waking up. Participants obtained these 
data for one complete menstrual cycle, starting with the phase randomly allocated (tympanic 
temperature; EFP: 36.34 ± 0.42; LFP: 36.43 ± 0.62; MLP: 36.42 ± 0.47 °C, body mass; EFP: 58.86 ± 9.28; 
LFP: 58.89 ± 9.14; MLP: 59.03 ± 9.11 kg). In addition, participants were supplied with 7 reactive test 
strips (One Step Ovulation LH Test Strip; CVS Health, Woonsocket, RI, US) to assess any increase in 
the luteinizing hormone in the first-morning urine sample. With all this information, the following 
events were used to determine the onset of each phase, as follows: EFP was indicated by the onset of 
menses; LFP was indicated by a positive test for urinary luteinizing hormone; MLP was determined 
to be between 70% and 75% of the individual menstrual cycle length (i.e., from the 20th to 22th day 
of the menstrual cycle for a regular cycle of 28 days [21]). All these protocols helped to align the 
participants’ cycles and therefore, despite different cycle lengths, participants performed the testing 
in the same cycle phases. 
2.6. Statistical Analysis 
Data were collected as previously indicated and the results of each test were blindly introduced 
into the statistical package SPSS v 20.0 (IBM company, New York City, NY, US) for later analysis. 
Normality was tested for each variable with the Shapiro–Wilk test. All included variables in this 
investigation presented a normal distribution (P > 0.05) and parametric statistics were used to 
determine the ergogenicity of caffeine. The caffeine-placebo differences in mean and peak velocity 
were identified using a two-way ANOVA with repeated measures (treatment × load). After a 
significant F test, differences among means were identified using the Bonferroni post hoc procedure. 
The significance level was set at P ≤ 0.05. The results are presented as means ± SD. To improve the 
identification of meaningful differences, the effect size was also calculated in all caffeine-placebo 
pairwise comparisons to allow a magnitude-based inference approach [24]. The effect-size statistic 
±90% confidence intervals (CI) was used on log transformed data to reduce bias due to non-
uniformity of error. The smallest significant standardized effect threshold was set as 0.2. Ranges of 
likelihood <1% indicated almost certainly no chances of change; 1% to 5%, very unlikely; 5% to 25%, 
unlikely; 25% to 75%, possible; 75% to 95%, likely; 95% to 99%, very likely; >99%, most likely. 
Differences were rated as unclear when likelihood exceeded >5% in both positive/negative directions. 
Effect sizes were interpreted according to the following ranges: <0.2, trivial; 0.2–0.6, small; 0.6–1.2, 
moderate; 1.2–2.0, large; 2.0–4.0, very large and; >4.0, extremely large [24]. 
3. Results 
Figure 2 displays mean and peak velocity differences between caffeine and the placebo for all 
the loads under investigation. In comparison to the placebo, the two-way ANOVA showed that the 
ingestion of 3 mg/kg/bm of caffeine increased mean velocity at 60% 1RM in EFP (Δ = 1.4 ± 2.7%, P = 
0.04) and LFP (Δ = 5.0 ± 10.4%, P = 0.04). No other differences were identified with the two-way 
ANOVA in mean or peak velocity. However, the magnitude-based inference approach showed that, 
in EFP, mean velocity was likely higher at 20% 1RM (Δ = 2.9 ± 4.0%, chance% as 
positive/trivial/negative = 55/45/0%) with placebo than with caffeine. In EFP, mean velocity was 
possibly higher at 40% 1RM (Δ = 3.1 ± 5.7%; 55/44/1%) with caffeine than with the placebo (Figure 2, 
panel A). In LFP, mean velocity was possibly higher at 40% 1RM with caffeine than with the placebo 
(Δ = 3.7 ± 8.7%; 63/35/2%). In MLP, mean velocity was likely higher at 20% (Δ = 5.4 ± 8.7%; 85/14/1%), 
and 40% 1RM (Δ = 6.1 ± 9.1%, 85/15/0%) and possibly higher at 60% (Δ = 5.3 ± 12.1%; 70/28/2%), and 
80% 1RM (Δ = 4.7 ± 14.7%; 54/43/3%) with caffeine than with the placebo.  
For peak velocity, it was very likely that this variable was higher with placebo at 20% 1RM (Δ = 
3.1 ± 5.7%, 55/44/1%) and possibly higher with caffeine at 40% 1RM (Δ = 3.1 ± 5.7%; 55/44/1%) in the 
EFP (Figure 2, panel B). Caffeine induced possible ergogenic effects on peak velocity at 20% (Δ = 3.1 
± 4.3%, 53/47/0%), 40% (Δ = 3.9 ± 7.9%, 63/35/1%), and 60% 1RM (Δ = 2.8 ± 7.7%, 60/36/4%) in the LFP 
with no trivial or unclear effects in the MLP. 
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Figure 2. Changes induced with the ingestion of 3 mg/kg/bm of caffeine on mean velocity (A) and 
peak velocity (B) during the concentric phase of the Smith machine half-squat exercise of increasing 
loads (20%, 40%, 60% and 80% of one repetition maximum; 1RM) in each phase of the menstrual cycle. 
Data are mean ± standard deviation from 13 eumenorrheic athletes. The information over the data 
corresponds to the caffeine-placebo effect size statistic ±90% confidence intervals and magnitude base 
inference of this comparison. (*) Caffeine different from placebo within the same menstrual cycle 
phase at P < 0.05. 
4. Discussion 
The current body of evidence has found that acute caffeine intake (i.e., 5–6 mg/kg/bm) is able to 
increase muscle strength and power in women [1,8–10], although the ergogenic effect of this 
substance was small in all these investigations. However, previous research protocols on this topic 
did not consider the menstrual cycle phase in which the caffeine ergogenicity was found, despite the 
potential interaction between female sex hormones and caffeine [13,14]. To the authors’ knowledge, 
this is the first study to directly compare the ergogenic response to caffeine on resistance exercise 
performance during the different phases of the menstrual cycle. Using a repeated-measures design 
in which the onset of the menstrual cycle phase was carefully delimited, caffeine-placebo 
comparisons were made in the early follicular, late follicular and mid-luteal phases while muscle 
performance was measured during a half squat force-velocity relationship. By using a traditional 
statistical approach, the two-way ANOVA revealed only subtle ergogenic effects of caffeine on mean 
and peak velocity in the half squat exercise. However, the magnitude-based inference approach 
indicated that caffeine was able to produce small ergogenic effects on mean and peak velocity at 
several loads (Figure 2) with a tendency to move the force-velocity relationship upwards in all phases 
of the menstrual cycle. Overall, the magnitude of these effects was comparable in all the three 
menstrual cycle phases under investigation. Taken together, these data suggest that caffeine might 
have a potential to enhance maximal velocity of movement in half-squat exercise. Although this effect 
was equally present during the menstrual cycle, the effect was catalogued as of small magnitude. 
The concentration of the main female sex hormones fluctuates during different phases of the 
menstrual cycle provoking changes in physiological functions and performance [25–27]. The ovarian 
hormones estrogen and progesterone provoke opposing physiological functions—while estrogen is 
a hormone with a purported anabolic function, progesterone has been related to catabolic pathways 
[21,28]. For this reason, it has been speculated that muscle performance and muscle adaptations might 
be favored when estrogen concentration is high and progesterone is low (i.e., follicular phase). In fact, 
although muscle performance seems unaffected during the menstrual cycle [29], concentrating most 
of the resistance training in the follicular phase induces greater changes in muscle strength and 
hypertrophy compared to concentrating resistance training in the luteal phase [30]. In addition, the 
intake of 2 mg/kg/bm of caffeine produces greater caffeine-induced cardiovascular and mood 
changes in the follicular vs. the luteal phase [13,20]. Together, these effects might indicate that acute 
caffeine intake will produce a higher caffeine ergogenicity in the follicular phase.  
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Interestingly, this speculation was not confirmed by our data because caffeine presented a 
similar ergogenic effect to increase mean velocity in the early follicular, late follicular and mid luteal 
phases (Figure 2). Caffeine produced a negative effect on peak velocity at 20% 1RM in the early 
follicular phase of the menstrual cycle. However, this negative effect was not found in the remaining 
loads of this menstrual cycle phase nor in peak velocity values of the late follicular and mid luteal 
phases. In the author’s opinion, this lack of effect of acute caffeine intake at 20% 1RM in the early 
follicular phase is anecdotical and does not alter the overall positive effect of caffeine to increase 
velocity during half-squat exercise (Figure 2). Caffeine produced this positive effect in the mid-luteal 
phase despite the probable high serum concentration of progesterone at this time of the menstrual 
cycle [15]. Although we did not assess serum caffeine concentrations, it is presumable that the stable 
caffeine metabolism during the menstrual cycle in these women who were not taken oral 
contraceptives [15,16] produced comparable serum caffeine concentrations in the early follicular, late 
follicular and mid luteal phases that promoted comparable ergogenicity for muscle performance. 
This finding is novel and reflects the high potential capacity of acute caffeine intake to produce 
increases in muscle performance in women, as previously found in other exercise and sport 
disciplines [31–33]. In this case, these data are novel because suggests that the magnitude of the 
caffeine ergogenic effect is comparable across the menstrual cycle.  
Nevertheless, it is very important to take into account the individual responses during the 
menstrual cycle. In the current investigation, eumenorrheic women with no menstrual disorders were 
selected as the study sample to avoid the possible effects of these symptoms on the results of the 
pairwise caffeine-placebo comparisons. However, there is a high percentage of athletes who report 
premenstrual symptoms that might ultimately decrease performance [34]. Unfortunately, the results of 
this investigation cannot be used to ascertain whether caffeine might be used to avoid or to reduce the 
performance detriments produced by any menstrual disorder and further investigation about the 
effects of caffeine in these populations is warranted. The ergogenic effect of caffeine on muscle 
performance in women taking oral contraceptives should also be investigated because ethinylestradiol, 
one of the substances included in contraceptive pills, decreases caffeine metabolism [17].  
There are several limitations to this experiment that should be mentioned and discussed to 
understand its scope. Firstly, to determine the onset of the menstrual cycle phases there was no 
measure of the concentration and/or quantity of female steroids hormones. However, we used a 
menstrual period tracker application, and measured changes in tympanic temperature and body 
mass. In addition, we also used luteinizing hormone urine test strips, as previously recommended 
[12,35]. Secondly, although the participants who underwent this protocol had at least six months of 
resistance training experience, they had no experience in velocity-based training. Lastly, we only used 
a dose of 3 mg/kg/bm of caffeine which is lower than the 5–6 mg/kg/bm used in previous 
investigations on caffeine effects on muscle performance. In addition, we selected low caffeine users 
while it is possible that higher doses are necessary to find an ergogenic effect of caffeine in women 
habituated to caffeine intake, as this has been demonstrated in male athletes [36]. Thus, it is possible 
that the magnitude of the ergogenic effect on mean and peak velocity found in this investigation was 
affected by the dose and the lack of tolerance to this drug. 
5. Conclusions 
In summary, the pre-exercise ingestion of 3 mg/kg/bm of caffeine increased, to a similar extent, 
mean and peak velocity in the half squat exercise at increasing loads in the early follicular, late 
follicular, and mid luteal phases of eumenorrheic trained athletes. Thus, in eumenorrheic women, 
caffeine might have the potential of increasing muscle performance during the menstrual cycle, 
although 3 mg/kg/bm would produce an effect of small magnitude. The outcomes of this 
investigation suggest that eumenorrheic female athletes might use acute caffeine intake to increase 
movement velocity during resistance training routines. The use of caffeine might be used to increase 
maximal strength values on different strength-based exercises [37]. In addition, it has been recently 
found that resistance training performed at fast movement velocities offers superior muscular 
strength gains than resistance training with slow-to-moderate velocities [38]. Thus, the use of caffeine 
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before resistance training might be effective to enhance muscle adaptation derived from long-term 
strength training, although such hypothesis deserves further confirmation. In this sense, caffeine 
ergogenicity for resistance exercise can be equally obtained in all phases of the menstrual cycle and 
then, the supplementation with caffeine can be used to design strength training programs without 
any interference with athletes’ menstrual cycle.  
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